An Open-label, Multi-Centered, Dose Escalation Phase Ib Study (Expansion Stage) of Epitinib (HMPL-813) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Epitinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Hutchison MediPharma
- 21 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 21 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2019.
- 29 Nov 2016 Results published in the Chi-Med Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History